In chronic myeloid leukemia (CML) stem/progenitor cells, CaMKIIγ activity sustains survival pathways including NF-κB and Wnt/β-catenin; genetic knockdown or pharmacologic inhibition with berbamine suppresses leukemic “stemness” and prolongs survival in preclinical models [66]. Here, NFKB1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.